Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Nov 13, 2009

Premium

Varian last week launched the 325-MS triple-quadrupole LC-MS for the high-throughput detection and identification of chemical compounds.

The instrument is Varian's next-generation LC-MS triple-quad mass spectrometer and features the company's vESI ion source — "a vortex ESI ion source that improves sensitivity by increasing the efficiency of the desolvation process," Varian said in a statement.

According to Varian, "a vortex of drying-gas facilitates ion desolvation at lower temperatures accommodating a wider range of flow rates for small molecule analysis as well as biomolecules without compromising system performance."


Agilent Technologies this week launched the 1290 Infinity LC Injector HTS/HTC sample injection system.

According to the firm, the system offers fast speed, ultra-low carryover, and robustness for customers in need of high throughput. The injectors are the first high-throughput sample injection modules providing 1290 Infinity LC pressure capability at 1200 bar, the company said.

Agilent launched the 1290 system in April [See PM 04/30/09].

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.